Pharma: Pharma has to find new growth pills as Covid booster wears off

The overall under-performance of the US business vis-a-vis other businesses is likely to continue in the absence of any fresh triggers. Improving R&D investments and increasing R&D productivity is going to be one of the major challenges for the companies in the sector.

Synopsis

The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.

ET Intelligence Group: With the weekly pandemic death toll reaching the lowest worldwide last week since March 2020, the World Health Organization has indicated the end of Covid-19 may be in sight.

However, going by the performance of the pharma sector on the bourses, the pandemic probably ended much before for the sector – a standout straggler on the stock market through the ‘reopening’ trade.

The ET Pharma Index is down 14% even as the

BY

ET Bureau

4 mins read, Last Updated:

Sep 16, 2022, 06:37 AM IST

Gift A Story

Share member-only stories with your friends or family and help them read it for free.

Gifting Limit Reached!

Hey , no more stories left for you to gift.

No worries! You will get a limit of 15 stories next month to share with your friends and family.

Gift This Story

Stories Left!

You can gift upto 15 stories in a month.

• FONT SIZE

  AbcSmall

  AbcMedium

  AbcLarge

• SAVE
• PRINT
• COMMENT

Continue reading with one of these options:

Limited Access

Free

Login to get access to some exclusive stories
& personalised newsletters

Login Now

Unlimited Access

Starting @ Rs120/month

Get access to exclusive stories, expert opinions &
in-depth stock reports

Subscribe Now

To read full story, subscribe to ET Prime

Get Unlimited Access to The Economic Times

₹34 per week

Billed annually at
₹2499 ₹1749

Continue

Already a Member? Sign In now

Already a Member? Sign In now

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Rs 49 for 1st month

Then Rs. 1,749 per year

SUBSCRIBE NOW

Valid only with UPI, Credit & Debit Cards Autopay

Choose Payment Mode & Plan

–

–

–

Subscribe Now

(Credit card mandatory)

You can cancel your subscription anytime

–

–

–

Subscribe Now

(Pay Using Netbanking/UPI/Debit Card)

Netbanking, Credit & Debit Card

Subscribe with Google

₹399/month

Monthly
PLAN

Billed Amount ₹399

₹399

₹208/month

(Save 49%)

Yearly
PLAN

Billed Amount ₹2,499

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

₹399

₹150/month

(Save 63%)

2-Year
PLAN

Billed Amount ₹3,599

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

Subscribe NowSubscribe with

Get ET Prime for just ₹2499 ₹1749/yr

Continue

Special Offer

Get Flat 20% Off

ON ET PRIME MEMBERSHIP

Avail Offer

Why ?

• Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

• Stock analysis. Market Research. Industry Trends on 4000+ Stocks

• Clean experience with
  Minimal Ads

• Comment & Engage with ET Prime community

• Exclusive invites to Virtual Events with Industry Leaders

• A trusted team of Journalists & Analysts who can best filter signal from noise